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Background:Cysteamine has recently been shown tohave in vitroproperties potentially therapeutically beneﬁcial
in cystic ﬁbrosis (CF). In this studywe investigated the antimicrobial andmucolytic activity of cysteamine against
the complex biologic matrix of CF sputum.
Methods: Sputum sampleswere obtained from23 CF adults. Sputumpolymicrobial content after in vitro exposure
to cysteamine and standard CF antibiotics was assessed after a single exposure and after 14 days low-dose expo-
sure. The effect of cysteamine on sputum spinnbarkeit was assessed.
Findings: Cysteamine reduced sputumpolymicrobial burden by 3 · 18 (95% CI 2 · 30–4 · 07, p b 0.001) log10 units
after 24 h incubation. Combined cysteamine and tobramycin reduced polymicrobial burden by a further 3 · 75
(95% CI 2 · 63–5 · 07, p b 0 · 001) log10 units above that seen with tobramycin. Repeated low dosing with cys-
teamine reduced sputum polymicrobial load from day 10 onwards (p= 0.032). Cysteamine reduced CF sputum
viscoelasticity, sputum spinnbarkeit cysteamine 11.1 mm/s (95% CI 3.95–18.2) vs DNAse 1.69 mm/s (95% CI
0.73–2.65), p=0.016. Cysteaminewas active againstMycobacterium abscessus as amonotherapy and also poten-
tiated the effects of amikacin and azithromycin.
Conclusion: Further investigation is required into the therapeutic potential of cysteamine in CF to treat emerging
as well as established microbial pathogens and as a mucolytic agent.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cystic Fibrosis (CF) is an autosomal recessively inherited disease
most prevalent in Caucasian populations of European origin (World
Health Organization, 2004). In the UK about 10,000 people have
CF, globally about 70–100,000 people are affected (World Health
Organization, 2004). Although CF is a multisystem condition themajor-
ity of CF associated morbidity andmortality is a consequence of chronic
suppurative lung disease and ultimately respiratory failure (UK CF
Registry, 2014; Goss and Quittner, 2007), currently median (95% CI)
age of death in the UK is 29 (27–31) (UK CF Registry, 2014). Infection
of the lower airways by Pseudomonas (Emerson et al., 2002), and
Burkholderia species (Muhdi et al., 1996; Jones et al., 2004) adversely
affects morbidity, quality of life and survival, and there are increasing
concerns about the consequences of infection with emergent (Lipuma,
2010) pathogen species such asMycobacterium abscessus (Esther et al.,n Children's Hospital, Aberdeen
.
. This is an open access article under2010; Hansen et al., 2006). In CF, Pseudomonas (Emerson et al., 2002)
and Burkholderia (Muhdi et al., 1996; Jones et al., 2004) species grow
in bioﬁlms and as such aremuchmore resistant to antibiotics compared
with planktonic-growing cells of the same isolate (Stewart and
Costerton, 2001). The aggressive use of antibiotics to suppress chronic
infection and to treat acute exacerbations has contributed to the in-
creased survival of peoplewith CF. However, increasing antibiotic resis-
tance, multiple antibiotic resistance and drug intolerance are emerging
as major clinical problems. These issues have led to calls for research
into new antimicrobial agents and new antibiotic strategies to target
the bioﬁlm and to increase the effectiveness of currently available anti-
biotics (Bals et al., 2011).
We have previously described the in vitro antimicrobial, anti-bioﬁlm
andmucoactive properties of cysteamine as amonotherapy and in com-
bination with CF guideline recommended antibiotics (Charrier et al.,
2014). Cysteamine has been routinely used to treat cystinosis for more
than 20 years and so a signiﬁcant body of clinical data already exists
as to its characteristics within this patient group. The antimicrobial
and mucoactive attributes of cysteamine described to date are poten-
tially therapeutically beneﬁcial in CF, not only in the treatment ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2014). An inherent limitation of the data derived thus far is that they
were generated frommonocultures of bacteriamost commonly isolated
from people with CF and against individual components of mucus. To in-
vestigate the potential of cysteamine in CF undermore physiologically ro-
bust conditions, we investigated its mucolytic and antimicrobial activity
against sputum from CF patients and report here for the ﬁrst time on its
rheological properties and antimicrobial action against the polymicrobial
content of CF sputum.Wealso report on the activity of cysteamine against
M. abscessus isolates from CF participants in this study.
2. Methods and Materials
2.1. Subjects
Patients attending the adult CF clinic at Aberdeen Royal Inﬁrmary,
Aberdeen, UK were invited to participate in a cross-sectional study in-
vestigating the antimicrobial properties of cysteamine in sputum from
people with CF. The inclusion criteria were: diagnosed CF associated
lung disease and able to spontaneously expectorate sputum; 57 patients
fulﬁlled the eligibility criteria and were invited to participate. Partici-
pants provided a sample of spontaneously expectorated sputum. The
clinical data collected included: age, sex, height, weight, ventilatory
function (FEV1) and CF genotype. Also recorded were the bacterial
species infecting the sputum (Lee et al., 2003) and whether the partici-
pantwas exacerbating, had a recent exacerbation (completed treatment
b4 weeks previously) or was clinically stable (exacerbation N4 weeks
previously). Antimicrobial therapy at the timeof samplingwas recorded
e.g. azithromycin, inhaled therapies. The study received ethical approval
(13/NS/0001) from theNorth of Scotland Research Ethics Service and all
participants provided written informed consent.
2.2. Chemicals and Growth Media
Tobramycin was purchased fromDiscovery Fine Chemicals (UK). All
other chemicals, growth media and antibiotics were obtained from
Sigma-Aldrich (UK).
2.3. Effect of Cysteamine and Antibiotics on CF Sputum Microbial burden:
Single Exposure
Sputum sampleswere processed for antimicrobial activity within 4 h of
collection. To assess the antimicrobial impact of cysteamine alone and cys-
teamine in conjunction with antibiotics commonly used to treat infective
exacerbations of CF lung disease, 0 · 2 ml of each sputum sample sputum
was diluted tenfold in sterile phosphate buffered saline (PBS) and vortexed.
Aliquots (0 · 2 ml) of the homogenised diluted sample were exposed to
cysteamine only (1 mg/ml) (Charrier et al., 2014), antibiotic (tobramycin
[0 · 1mg/ml] or ciproﬂoxacin, [0 · 1mg/ml] only), cysteamine plus antibi-
otic or vehicle (PBS) only, for 4 h and 24 h at 37 °C. Sputum samples were
then serially diluted tenfold (1 × 10−1 to 1 × 10−8) and spread-plated on
non-selectivenutrient agarplates. Cultureswere incubated at 37 °Cand col-
ony forming units per ml (cfu/ml) of bacteria quantiﬁed at 48 h.
2.4. Determination of CF Sputum Microbial Burden: Multiple Exposures
To assess any impact of cysteamine on sputum microbial burden in
CF at pharmacological concentrations reported in vivo, multiple dosing
experiments were conducted. In these assays, 0 · 2 ml of sputum
were exposed daily (ﬁrst dosing within 4 h of collection as above) to
2 μg/ml of cysteamine, or PBS as a control, for 14 days. 2 μg/ml is a
level typically reported when dosing with cysteamine in patients with
cystinosis (Langman et al., 2012). On alternate days, 10 μl of each sam-
ple was recovered and serially diluted tenfold (1 × 10−1 to 1 × 10−8)
and spread-plated on non-selective nutrient agar plates. Cultures were
incubated at 37 °C and cfu/ml of bacteria quantiﬁed at 48 h.2.5. Quantiﬁcation of CF Sputum Macrorheological
Properties (spinnbarkeit)
Macrorheological analysis was conducted within 4 h of collection of
sputum samples. Aliquots (0 · 2 ml) of sputum were incubated for 1 h
at 37 °C after the addition of cysteamine (1 mg/ml), PBS or DNAse
(500 U/ml). The treated sputum samples were was then transferred to
the open end of a 2 ml graduated pipette (Greiner, UK) which was se-
cured vertically. Each sputum sample was allowed to descend inside
the pipette under gravity. This process was timed and ﬁlmed, and the
velocity of the sputum was calculated as distance travelled over time
taken in mm/s.
2.6. Antimicrobial Susceptibility ofMycobacteria Abscessus Sputum Isolates
in vitro
M. abscessus complex (MAC) was isolated from three participating
patients. The susceptibility of these isolates, plus the MAC type strain
M. abscessus DSMZ44196 to the antimicrobial effects of cysteamine
alone and to cysteamine combined with antibiotics employed in MAC
eradication strategies (amikacin, azithromycin and meropenem) was
assessed by CLSI broth microdilution procedure (Clinical and Laboratory
Clinical Institute, 2012) and checkerboard assay respectively.
2.7. Statistical Considerations
FEV1 was expressed as a percentage of predicted using GLI 2012
(Quanjer et al., 2012) reference equations. Sputum microbial load
expressed as colony forming units approximated to a log-normal distri-
bution and was therefore expressed as mean log10 (95% conﬁdence in-
terval). The microbial load of CF sputum samples after incubation with
cysteamine, tobramycin, ciproﬂoxacin or combinations thereof after
4 h and 24 h was modelled using two way repeated measures ANOVA
with post hoc testing using Bonferroni adjustment. Analyses were per-
formed using IBM SPSS Statistics for Windows, v22 · 0 (Armonk, NY).
2.8. Role of the Funding Source
This study was funded by Scottish Enterprise. The funder did not
contribute to study design, data collection, analysis, this report or the
decision to publish.
3. Results
3.1. Patient Population
Twenty three of the eligible 57 patients participated in the study,
each provided a sputum sample, their clinical characteristics are
outlined in Table 1. All of the 15 patients infected with Pseudomonas
aeruginosa were infected by at least one mucoid strain.
3.2. Antimicrobial Activity of Cysteamine Against Polymicrobial Burden in
CF Sputum
The antimicrobial activity of tobramycin, cysteamine and combined
tobramycin/cysteaminewere tested in all 23 samples and are presented
in Fig. 1. Cysteamine reduced sputum polymicrobial load after 4 h in
sputum samples from 20 patients and from 21 patients after 24 h.
When compared with untreated samples tobramycin, cysteamine and
combined cysteamine/tobramycin reduced polymicrobial load at 4 h
and 24 h (all p b 0.001). Overall, tobramycin, cysteamine and combined
cysteamine/tobramycin signiﬁcantly (p b 0 · 001) reduced polymicrobial
load by 1 · 42 (95% CI 0 · 92–1 · 92), 3 · 18 (95% CI 2 · 30–4 · 07), and
3 · 86 (95% CI 3 · 11–4 · 61) log10 units respectively. When compared
with tobramycin, cysteamine further reduced polymicrobial load by
1 · 76 (95% CI 0 · 89–2 · 63, p b 0 · 001) log10 units. When compared
Table 1
Clinical characteristics of participating patients.
All subjects (n = 23) Ciproﬂoxacin subgroup (n = 9) Low dosing subgroup (n = 13) Rheology subgroup (n = 6)
Age (yrs) (median, IQR) 28 (19–36) 24 (19–37) 29 (19–36) 24 (19–45)
Female (n,%) 13 (57%) 6 (67%) 6 (46%)
DF508homozygous (n,%) 16 (70%) 8 (89%) 9 (69%) 5 (83%)
DF508heterozygous 6 (26%) 1 (11%) 3 (23%) 1 (17%)
DF508 negative 1 (4%) 0 1 (8%) 0
BMI (mean 95% CI) 22.1 22.0 22.4 22.3
(20.9–23.3) (19.1–24.9) (20.5–24.4) (17.6–27.0)
FEV1% predicted (mean 95% CI) 62% (49–74) 54% (37–70) 69 (52–85) 53% (29–77)
Last exacerbation (n,%)
Acute 9 (39%) 5 (56%) 5 (39%) 3 (50%)
b4 weeks 8 (35%) 3 (33%) 6 (46%) 2 (33%)
N4 weeks 6 (26%) 1 (11%) 2 (15%) 1 (17%)
Concomitant medication
Azithromycin (n,%) 20 (87%) 9 (100%) 11 (85%) 6 (100%)
Inhaled antibiotic (n,%) 20 (87%) 8 (89%) 12 (92%) 5 (83%)
Ivacaftor (n,%) 2 (9%) 0 0 0
Sputum culture (n,%)
Staphylococcus aureus 4 (17%) 1 (11%) 3 (23%) 1 (17%)
Pseudomonas aeruginosa 15 (65%) 6 (67%) 8 (62%) 5 (83%)
Burkholderia species 4 (17%) 2 (22%) 2 (15%) 0
Stenotrophomonas maltophilia 2 (9%) 1 (11%) 2 (15%) 1 (17%)
Mycobacterium abscessus 3 (13%) 0 0 0
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polymicrobial load by 1.03 (95% CI−0 · 50–1 · 56, p = 0 · 001) log10
units above that observed with tobramycin. After 24 h of exposure
cysteamine/tobramycin further reduced polymicrobial load by 3 · 75
(95% CI 2 · 63–5 · 07, p b 0 · 001) log10 units above that seen with
tobramycin (5.65, 95% CI 4.46–6.80).
There was sufﬁcient sputum to test antimicrobial activity of cipro-
ﬂoxacin, cysteamine and combined ciproﬂoxacin/cysteamine in nine
samples, the clinical characteristics of this subgroup are presented in
Table 1 and the results are presented in Fig. 2.When comparedwith un-
treated samples cysteamine and combined cysteamine/ciproﬂoxacin
reduced polymicrobial load at 4 h and 24 h (all p b 0.005), ciproﬂoxacin
reduced polymicrobial load at 24 h (p = 0.001) but not at 4 h (p =
0.234). Overall ciproﬂoxacin, cysteamine and combined cysteamine/
ciproﬂoxacin signiﬁcantly reduced polymicrobial load by 0 · 84 (95%
CI 0 · 29–1 · 39, p = 0 · 008), 2 · 76 (95% CI 1 · 32–4 · 20, p =
0 · 002), and 2 · 86 (95% CI 1 · 68–3 · 98, p b 0 · 001) log10 units respec-
tively. When compared with ciproﬂoxacin, cysteamine further reduced
polymicrobial load by 1 · 92 (95% CI 0 · 85–3 · 00, p = 0 · 003) log10
units. Overall when compared with ciproﬂoxacin combined cysteamine/Fig. 1.The antimicrobial activity of tobramycin, cysteamine and combined tobramycin and
cysteamine on polymicrobial load after 4 and 24 h exposure. Bacterial load expressed as
mean (95% conﬁdence interval).ciproﬂoxacin further reduced polymicrobial load by 1 · 99 (95% CI
1 · 02–2 · 96, p b 0 · 001) log10 units, however combined cysteamine/
ciproﬂoxacin did not reduce polymicrobial load over and above that
achieved by cysteamine alone.
Inclusion of clinical factors in the repeated measures ANOVA analy-
sis demonstrated that sex, CF genotype, FEV1, exacerbation status, or
concomitant use of azithromycin, inhaled antibiotics or ivacaftor did
not modify the antimicrobial effects reported above.
3.3. Antimicrobial Activity of Cysteamine at a Pharmacological Concentration
in CF Sputum
The effects of in vitro daily dosing of sputum from 13 CF patients
with 2 μg/ml cysteamine and PBS over a twoweek period are presented
in Fig. 4, the clinical characteristics of this subgroup are presented in
Table 1. This dose of cysteamine is typical of the plasma levels observed
in patients with cystinosis after dosing with cysteamine (Clinical and
Laboratory Clinical Institute, 2012). Cysteamine signiﬁcantly reduced
the polymicrobial burden in CF sputum (Greenhouse–Geisser correctedFig. 2. The antimicrobial activity of ciproﬂoxacin, cysteamine and combined ciproﬂoxacin
and cysteamine on polymicrobial load after 4 and 24 h exposure. Bacterial load expressed
as mean (95% conﬁdence interval).
Fig. 3. Effect of cysteamine on CF sputumviscoelasticity comparedwith control andDNAse
I treated sputum taken from 6 patients. Sputum velocity expressed as mean (95%
conﬁdence interval).
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10 days of treatment was lower with cysteamine but this was only
signiﬁcant for day 10 (p = 0 · 044) but not day 14 (p = 0 · 088).
3.4. Sputum Macrorheology/spinnbarkeit
The effect of cysteamine on sputum spinnbarkeit was tested in
samples from six participants where the volume of sputum provided
permitted analysis, the clinical characteristics of this subgroup are pre-
sented in Table 1. Cysteamine was a potent mucolytic in all CF sputum
samples tested, outperforming human recombinant DNAse I (p =
0 · 016), a widely used mucolytic in the CF-ﬁeld (Bilton and Stanford,
2014), in its reduction of sputum viscoelasticity after 1 h treatment at
37 °C (Fig. 3). The effect on sputum spinnbarkeit after 1 h is demonstrat-
ed in the Video clip Fig. 5, but improvements in sputumviscosity treated
with cysteamine were rapid and noticeable even after 5 min (data not
shown).
3.5. Antimicrobial Susceptibility of Mycobacterium Abscessus Sputum
Isolates in vitro
TheM. abscessus isolated from three of the study subjects (in whose
sputum samples a signiﬁcant reduction in polymicrobial burden was
brought about with exposure to cysteamine and cysteamine plusFig. 4. The antimicrobial activity of cysteamine (2 μg/ml) administered daily on sputum
polymicrobial load over two weeks. Bacterial load expressed as mean (95% conﬁdence
interval).tobramycin or ciproﬂoxacin) were all sensitive to the antimicrobial
effects of cysteamine (MIC range 62 · 5–250 μg/ml) when tested
in vitro, as was the type strain DSMZ44196 (Table 2). Furthermore,
cysteamine potentiated the impact of amikacin in both clinical and type
strains, and azithromycin in all but one clinical strain, with fractional in-
hibitory concentration indices (FICI) (Vanhoof et al., 1978; Choi et al.,
2012) demonstrating the more than additive or synergistic potential
of combined therapy. Cysteamine had concentration-dependent effects
on meropenem sensitivity in the clinical isolates and type strain of
M. abscessus tested, showing some concentration-speciﬁc antagonism.
4. Discussion
Cysteamine is an aminothiol (HSCH2CH2NH2) endogenously present
at very low levels as a consequence of coenzymeAmetabolism (Besouw
et al., 2013; Orloff et al., 1981). In the US and EU, cysteamine has
been licensed for the treatment of nephropathic cystinosis for over 20
years. In this observational study the in vitro antimicrobial and
mucoactive properties of cysteamine were tested in sputum samples
from adults with CF infected with bacteria typical of those reported in
the UK CF population (Staphylococcus aureus, P. aeruginosa, Burkholderia
species and Stenotrophomonas maltophilia). Cysteamine reduced spu-
tumpolymicrobial load ex vivo and at the doses tested this antimicrobial
effect was greater than that observed for tobramycin and ciproﬂoxacin.
The combination of cysteamine with tobramycin appeared to be more
than additive after 24 h incubation, being greater than the individual
effects of cysteamine or tobramycin. The combination of cysteamine/
ciproﬂoxacin appeared to be no more antimicrobial than cysteamine
alone, althoughwe have previously demonstrated a synergistic interac-
tion for these two compounds in vitro (Charrier et al., 2014). Whilst the
lack of synergy between cysteamine and ciproﬂoxacin may merely be a
consequence of the small number of sputum samples analysed (n= 9),
it may be that in the matrix of sputum the combination of cysteamine/
ciproﬂoxacin is unable to exert the additive effect present when
cultured under standard media conditions, further work is required
to investigate whether in vivo there is synergy between cysteamine
and ciproﬂoxacin. In our present study, we also demonstrated that
M. abscessus is sensitive to cysteamine;more so than for other CF bacte-
ria when tested in vitro as a monotherapy. Cysteamine also potentiates
the activity of other antimicrobial agents. In addition to cysteamine's
antimicrobial effects, in vitro, cysteamine had mucolytic effects, reduc-
ing sputum viscosity 8–9 fold, notably cysteamine had more potent
(6–7 fold)mucolytic effect than recombinant DNAse.We demonstrated
that the antimicrobial effects of cysteamine were not modiﬁed by clini-
cal factors e.g. sex, lung function, exacerbation status nor by concurrent
medication e.g. azithromycin, inhaled antibiotics or ivacaftor. However,
these analyses were of small numbers of patients and lacked statistical
power, further work is required to determinewhether any antimicrobial
effects of cysteamine are modiﬁed by concurrent medications, or other
factors e.g. disease severity, sex, age.
Previous in vitro studies using type strains andmonocultures of bac-
terial pathogens have shown cysteamine to have direct antimicrobial
activity with MIC100 at concentrations in the range of 250–500 μg/ml
(in nutrient rich media) against P. aeruginosa and other CF pathogens
including Burkholderia cepacia complex, S. aureus and also emerging
pathogens including Achromobacter xylosoxidans, and Stenotrophomonas
species (Charrier et al., 2014). The current study is a more clinically rele-
vant investigation because cysteamine was exposed to polymicrobial
populations of CF-associated pathogens in their natural clinical matrix
i.e. sputum from patients with CF. The data derived are a progression
from, and concur with previous observed in vitro antimicrobial and
mucolytic effects.
The present study demonstrates that cysteamine is antimicrobial
and mucoactive within CF sputum. It has also been shown that cyste-
amine rescues the functional expression of the F508del CF transmem-
brane conductance regulator (CFTR) in CFTR F508del homozygous
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1511G. Devereux et al. / EBioMedicine 2 (2015) 1507–1512mice. In a study of 10 F508del homozygous patients with CF aged 8–25
years the sequential administration of oral cysteamine and the green tea
ﬂavonoid epigallocatechin gallate (EGCG) improved CFTR function,
decreased sweat chloride concentrations and reduced sputum TNF
and CXCL8 protein levels (De Stefano et al., 2014). In the present
study, the effects of cysteamine are independent of CFTR genotype, sug-
gesting that future trials of cysteamine as an antimicrobial-mucolytic
should not be limited to F508del homozygous patients with CF. Thiols
such as cysteamine and N-acetylcysteine have many biological proper-
ties, the mucolytic effects of cysteamine are likely to be a consequence
of the thiol moiety reducing disulphide bonds in mucus proteins,
disrupting their ligand bonding and structure (Samuni et al., 1830).
N-acetylcysteine has also been shown to have antimicrobial and
antibioﬁlm activity and synergy with ciproﬂoxacin against P. aeruginosa
has been inconsistently reported (Zhao and Liu, 2010). The antibioﬁlm
activity of N-acetylcysteine has been attributed to thiol disruption of
disulphide bonds in enzymes involved in bioﬁlm synthesis, it is possible
that similar effects on proteins involved in gene expression, signalling
and cell cycling underlie the antimicrobial effects of cysteamine.
Thedoses of cysteamine applied for the single exposure experiments
in the present study were four times the median MIC100 previously
established for cysteamine against CF associated pathogens in
nutrient-rich media (Charrier et al., 2014). Presently we do not know
what, if any, local levels of cysteaminemay be achievable in the sputum
of CF patients after oral or aerosol delivery. It is known however, that in
patients with cystinosis, after a single standard dose of cysteamine at
steady state, peak plasma concentration is 2–3 μg/ml (Langman et al.,
2012). In an attempt to evaluate ex vivo the effects of cysteamine at
these much lower concentrations, sputum samples were exposed
daily to 2 μg/ml cysteamine for 14 days. The data from these experi-
ments suggest that signiﬁcant reductions in total microbial sputum
burden are likely to be achieved if cysteamine were to be used as an
adjunct to conventional antimicrobial therapy for the typical 14 day
course used to treat acute infective exacerbations of CF lung disease.
Consideration of the physical properties of cysteamine predict that
in vivo the antimicrobial effect of 14 days oral cysteamine is likely to
be greater than that observed in the current study.With an acid dissoci-
ation constant (pKa) of 10.4, and a partition coefﬁcient (logP) of 0.01
(Drugbank), cysteamine is likely to pass from the systemic circulation
into the acidic bronchial secretions (pH 6.0–6.9) (Palmer et al., 2007)
such that the concentration of cysteaminewill be higher in thebronchial
secretions than in the systemic circulation.
A key consideration when developing any potential new antimicro-
bial strategy, particularly one based on a broad-spectrum agent, is its
impact on resistance and whether modifying the existing microbiome
creates niches for additional, emerging pathogens. It will be very difﬁ-
cult to establish until introduction into clinical practice whether this is
the case for cysteamine, but there is now in vitro and ex vivo evidence
that cysteamine is active against emerging pathogens. We have already
reported antimicrobial activity against species such as Achromobacter
species and Stenotrophomonas species (Charrier et al., 2014) and in
the current studywe have furthered this work by investigatingwhether
cysteamine has antimicrobial activity against the emerging pathogen
M. abscessus. The prevalence of M abscessus infection in patients with
CF is increasing and there is great clinical concern since thismicroorgan-
ism is multidrug resistant and patient to patient transmission has been
recently demonstrated (Bryant et al., 2013). Three of the participants
in this study were infected with M. abscessus and their isolates were
all clearly sensitive to cysteamine when tested in vitro, not only as
a monotherapy but particularly in combination with amikacin and
azithromycin. Although the strains tested were already sensitive to
amikacin as deﬁned by CLSI breakpoints, this sensitivity increased
markedly in each of the strains tested. The same was true for the
M. abscessus type strain. Indeed the MIC100 for cysteamine against
M. abscessus was lower than we previously reported for Pseudomonas
species and all other CF pathogens. The identiﬁcation of an orally active
1512 G. Devereux et al. / EBioMedicine 2 (2015) 1507–1512agent against M. abscessus could be potentially useful, the synergism
between cysteamine and amikacin and azithromycin could be advanta-
geous in the protracted continuation phase of M. abscessus therapy,
however the dose-dependent antagonism of meropenemmay preclude
the use of cysteamine in the initial intensive phase of treatment.
Although this study has identiﬁed a potentially useful drug for the treat-
ment of patients with CF infected with M. abscessus, only four isolates
were tested in an extracellular in vitro context so further work is clearly
required.
The study we report here further supports continued development
of cysteamine as a novel “re-purposed” candidate CF treatment by
conﬁrming activity and therapeutic potential in the biological matrix
(CF sputum) and raises the prospect of cysteamine being used to treat
M. abscessus. It remains to be conﬁrmed however, the extent to which
oral cysteamine is absorbed and enters the bronchial secretions of
patients with CF. The tolerability of cysteamine when used in patients
with CF also needs to be ascertained because chronic oral cysteamine
therapy (in cystinosis) is associated with side-effects that could be
detrimental to the overall long term health of patients with CF, e.g.
anorexia, nausea, breath odour, lethargy, osteopenia and skin striae.
These side effects may not preclude the use of oral cysteamine as an ad-
junct to conventional antimicrobial treatment of acute infective exacer-
bations of CF lung disease. They could however, be problematic long
term, but overcome by the development of an inhaled form of cyste-
amine for chronic dosing.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2015.08.018.Author Contributions
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